Nemolizumab in Children Under 12: The Open Eczema Question
A new report asks whether nemolizumab, the IL-31-targeting biologic, can fill the treatment gap for children under 12 with moderate-to-severe atopic dermatitis.
Topic
Atopic Dermatitis
Topic
Atopic Dermatitis
Week 4 on Abrocitinib Predicts Week 12 Remission in Atopic Dermatitis
A JAAD study published October 17, 2026 finds week 4 abrocitinib response predicts week 12 remission in moderate-to-severe atopic…
Atopic Dermatitis Is Systemic, and 'Doing Nothing' Has a Cost
Dermatology Times argues untreated atopic dermatitis isn't neutral: reframed as a systemic inflammatory disease, inaction carries…
That Winter Itch May Not Be Dry Skin — It Could Be Eczema
A new report warns that persistent winter itching is not always dry skin — it may be eczema, a recurring inflammatory condition t…
Indian Dermatology Online Journal Publishes Comprehensive Abrocitinib Review
A comprehensive abrocitinib review in the Indian Dermatology Online Journal is now indexed on Ovid, widening access for dermatolo…
Inflammatory Caspases Drive IL-33 Release From Skin in Atopic Dermatitis
New research identifies inflammatory caspases as the enzymes that release IL-33 from skin in atopic dermatitis, implicating them…
First Human Data on Experimental Eczema Therapy Set for November
First-in-human data on an experimental eczema treatment arrives in November — from healthy volunteers, meaning safety, not effica…
Early-Life Factors May Predict Infant Eczema Risk, Study Finds
A new study suggests early-life factors could help clinicians flag infants at higher risk of eczema before the first flare, point…
Infant Skin Care: How Product Choice Shapes the Skin Barrier
Contemporary Pediatrics frames infant product selection around one criterion: protecting the immature skin barrier. Here's what t…
Dupilumab-Linked Vitiligo: Early Recognition and Alternative Agents
Research links dupilumab to new-onset vitiligo and points to early recognition, a nemolizumab switch, and targeted topical therap…